Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MDS confirmed within 2 weeks prior to study entry according to the World Health Organization (WHO) Criteria or the French-American-British (FAB) Classification.~* Trisomy 8 cytogenetics (simple or combined to other karyotypes) or patient classified as Intermediate-1 with bone marrow blasts equal to or greater than 5%, Intermediate-2 or High Risk MDS according to the IPSS score, or Patients with peripheral blood blasts equal to or greater than 5%.~* At least one cytopenia (Absolute Neutrophil Count \< 1800/µl or Platelet Count \<100,000/µl or Hemoglobin \< 10 g/dL).~* Failure of, or insufficient response to Azacytidine or Decitabine administered for 4 to 6 cycles in patients classified as Intermediate-2 or High risk or to Erythrocyte stimulating agents (failure or insufficient response defined as transfusion dependence or Hemoglobin remaining below 10 g/dl) in Low or Intermediate-1 Risk Trisomy 8 patients.~* Failed to respond to, relapsed following, or opted not to participate in bone marrow transplantation.~* Off all other treatments for MDS (including filgrastim (G-CSF) and erythropoietin) for at least four weeks. As an exception, filgrastim (G-CSF) can be used before, during and after the protocol treatment for patients with documented febrile neutropenia (\< 500/µl).~* ECOG Performance Status 0, 1 or 2.~* Willing to adhere to the prohibitions and restrictions specified in this protocol.~* Patient (or his/her legally authorized representative) must have signed an informed consent document indicating that he/she understands the purpose of and procedures required for the study and is willing to participate in the study.~Exclusion Criteria:~* Anemia due to factors other than MDS (including hemolysis or gastrointestinal bleeding).~* Hypoplastic MDS (cellularity \<10%).~* Any active malignancy within the past year except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.~* History of HIV-1 seropositivity.~* Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia.~* Active infection not adequately responding to appropriate therapy.~* Total bilirubin \> 1.5 mg/dL not related to hemolysis or Gilbert's disease, ALT or AST \> 2 X ULN.~* Serum creatinine \> 2.0 mg/dL or calculated creatinine clearance \< 60 ml/min/1.73 m\^2.~* Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of \<134 Meq/L).~* Women patients who are pregnant or lactating; Male patients with female sexual partners who are unwilling to follow the strict contraception requirements described in this protocol; Patients who do not agree to use adequate contraceptive \[including prescription oral contraceptives (birth control pills), contraceptive injections, intrauterine device (IUD), double-barrier method (spermicidal jelly or foam with condoms or diaphragm), contraceptive patch, or surgical sterilization\] before entry and throughout the study; Female patients with reproductive potential who do not have a negative serum beta-HCG pregnancy test at screening.~* Major surgery without full recovery or major surgery within 3 weeks of ON 01910.Na treatment start.~* Uncontrolled hypertension (defined as a systolic pressure equal to or greater than 160 mmHg and/or a diastolic pressure equal to or greater than 110 mmHg).~* New onset seizures (within 3 months prior to the first dose of ON 01910.Na) or poorly controlled seizures~* Any concurrent investigational agent or chemotherapy, radiotherapy or immunotherapy.~* Treatment with standard MDS therapies or investigational therapy within 4 weeks of starting ON 01910.Na.~* Psychiatric illness/social situations that would limit the patient's ability to tolerate and/or comply with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 800 mg/m^2 ON 01910.Na (Type: EXPERIMENTAL): 800 mg/m\^2 ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 48 hours (i.e. 2 consecutive 24-hour infusions) every week for the first 3 weeks of 4-week cycle.
- 1800 mg ON 01910.Na (Type: EXPERIMENTAL): 1800 mg ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 72 hours (i.e., 3 consecutive 24-hour infusions) every 2 weeks for the first four 2-week cycles and every 4 weeks afterwards.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete